<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The aim of this study was to evaluate the <z:chebi fb="32" ids="24621">endocrine</z:chebi> complications, in particular disorders of growth and thyroid function and <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism dysfunctions in patients treated with allo- and auto-haematopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: The investigated group consisted of: I </plain></SENT>
<SENT sid="2" pm="."><plain>16 patients after auto-HSCT (6 girls, 10 boys) aged 3-20 years (average 10,8+/-) because of <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (n=5), non Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=3), <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> (n=3), <z:e sem="disease" ids="C0751364" disease_type="Neoplastic Process" abbrv="">embryonal cancer</z:e> (n=2), <z:hpo ids='HP_0002885'>medulloblastoma</z:hpo> (n=1), Ewing's <z:hpo ids='HP_0100242'>sarcoma</z:hpo>/PNET (n=1), hyper <z:e sem="disease" ids="C0272191" disease_type="Disease or Syndrome" abbrv="">eosinophilic syndrome</z:e> (n=1) </plain></SENT>
<SENT sid="3" pm="."><plain>High dose chemiotherapy (HDC/T) included: BU/MEL (<z:chebi fb="0" ids="28901">busulfan</z:chebi>/melfalan) (n=7), BEAM (<z:chebi fb="0" ids="3423">carmustine</z:chebi>, eteposide, <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22599">arabinose</z:chebi>, melfalan) (n=3) </plain></SENT>
<SENT sid="4" pm="."><plain>II </plain></SENT>
<SENT sid="5" pm="."><plain>30 patients after allo-HSCT (20 girls, 10 boys) aged 3-17 years (average 9,56) </plain></SENT>
<SENT sid="6" pm="."><plain>Indication for HSCT was <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (n=11), <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (n=5), <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath>-<z:mp ids='MP_0005481'>CML</z:mp> (n=6), <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (n=2), non Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=1), juvenile myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n=1), severe aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (n=1), <z:e sem="disease" ids="C1260899" disease_type="Disease or Syndrome" abbrv="BDS">Blackfan-Diamond</z:e> <z:hpo ids='HP_0001903'>anaemia</z:hpo> (n=1), severe combined <z:hpo ids='HP_0002721'>immune deficiency</z:hpo> (n=1), <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo> (n=1) </plain></SENT>
<SENT sid="7" pm="."><plain>The patients underwent the following types of transplantation: HSCT of matched sibling donor (n=13), HSCT of matched unrelated donor (n=11) and HLA-mismatched related donor (n=6) </plain></SENT>
<SENT sid="8" pm="."><plain>The preparative regimens consisted of HDC/T usually BU/MEL (n=3); BU/CY/VP (<z:chebi fb="0" ids="28901">busulfan</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="4911">etoposide</z:chebi>) (6); BU/CY/ATG (anti-thymocyte globulin) (n=5), VP/ATG/TBI (total body irradiation) (n=3) </plain></SENT>
<SENT sid="9" pm="."><plain>19 children received CI (cranial irradiation) prior to grafting: auto-HSCT (n=6) and allo-HSCT (n=13) and 6 patients underwent TBI </plain></SENT>
<SENT sid="10" pm="."><plain>18 children received high steroid doses at least 28 days before transplant, 4 patients in the auto-HSCT group, and in the allo-HSCT group 14 patients before and 20 after HSCT procedure </plain></SENT>
<SENT sid="11" pm="."><plain>The analysis of thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free <z:chebi fb="4" ids="30660">thyroxine</z:chebi> (fT4), insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A1c (HbA1c), prolactine (PRL), oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test, growth hormone (GH test) and thyrotropin releasing hormone (TRH) test was performed in each case </plain></SENT>
<SENT sid="12" pm="."><plain>RESULTS: <z:hpo ids='HP_0000821'>Hypothyroidism</z:hpo> was found in 5 patients (3 after allo-HSCT, 2 after auto-HSCT) </plain></SENT>
<SENT sid="13" pm="."><plain>Thyroid hormone substitution was applied </plain></SENT>
<SENT sid="14" pm="."><plain>No case of <z:hpo ids='HP_0000836'>hyperthyroidism</z:hpo> was diagnosed </plain></SENT>
<SENT sid="15" pm="."><plain>Growth deficit was found in 8 patients (6 girls, 2 boys) between 13 to 70 months after allo-transplantation (average 36 months) </plain></SENT>
<SENT sid="16" pm="."><plain>Three children from the above group received CI </plain></SENT>
<SENT sid="17" pm="."><plain>Growth hormone substitution was applied in 1 girl (ALL, HLA MM REL, CI) </plain></SENT>
<SENT sid="18" pm="."><plain>An impaired excretion of GH after stimulation was diagnosed in 14 pts (10 after allo-HSCT, 4 after auto-HSCT) </plain></SENT>
<SENT sid="19" pm="."><plain>The growth process should still be observed in this subgroup </plain></SENT>
<SENT sid="20" pm="."><plain><z:hpo ids='HP_0000833'>Glucose intolerance</z:hpo> was found in 7 patients: in 4 treated with auto-HSCT and in 3 after allo-HSCT </plain></SENT>
<SENT sid="21" pm="."><plain><z:hpo ids='HP_0000819'>Diabetes mellitus</z:hpo> was diagnosed in none of them </plain></SENT>
<SENT sid="22" pm="."><plain>An <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> curve with increased excretion of insulin was diagnosed in 12 children </plain></SENT>
<SENT sid="23" pm="."><plain>CONCLUSIONS: Early endocrinological care is necessary in patients treated both with auto-HSCT and allo-HSCT due to high risk of <z:e sem="disease" ids="C0014130" disease_type="Disease or Syndrome" abbrv="">hormonal disorders</z:e> </plain></SENT>
</text></document>